Imanova Secures License from Cerveau Technologies, Inc. to Manufacture Investigational Tau Ligand, [18F]MK-6240

Invicro UK (formerly Imanova) has signed an agreement that grants the company the right to manufacture for distribution and on-site use [18F]MK-6240, an early stage investigational Positron Emission Tomography (PET) imaging agent. This will facilitate studies assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s Disease.

In January 2017 Cerveau Technologies, Inc. announced an exclusive license agreement with MSD, through a subsidiary, for the global development and commercialization of the early stage investigational imaging agent ([18F]MK-6240). Since then, Cerveau has been working with a growing set of pharmaceutical, biotech and academic collaborations to provide information about the status and progression of Alzheimer’s disease and other neurodegenerative diseases.

Invicro UK is now the latest, in a series of organizations, to secure the right to manufacture this tau ligand. “At Cerveau, we are focused on providing information and technologies to researchers and clinicians to improve brain health,” said Rick Hiatt, President of Cerveau Technologies, Inc. “We are excited by the opportunity to work with Invicro UK and the biotech industry in providing access to this novel imaging agent to the broader scientific community.”

Kevin Cox, Invicro UK’s CEO, said “The access to this ligand will allow us to advance the research into Alzheimer’s Disease and provide valuable information about the stages and progression of the disease. We look forward to this ongoing collaboration with Cerveau Technologies and their partner organizations.”